Dose-Exploration Evaluating the Efficacy and Safety of Voclosporin in Subjects With Focal Segmental Glomerulosclerosis

PHASE2TerminatedINTERVENTIONAL
Enrollment

5

Participants

Timeline

Start Date

June 21, 2018

Primary Completion Date

May 19, 2020

Study Completion Date

May 19, 2020

Conditions
Focal Segmental Glomerulosclerosis
Interventions
DRUG

Voclosporin

"Voclosporin softgel capsules. Up to 10 subjects will be enrolled into Cohort 1 and take up to 3 capsules twice daily (BID).~The dose of voclosporin for Cohort 2 (at least 10 subjects) will be determined by analysis of efficacy and safety data at Week 12 from the first 5 or 6 subjects in Cohort 1."

Trial Locations (23)

10032

FSGS Investigative Center, New York

18017

FSGS Investigative Center, Bethlehem

28204

FSGS Investigative Center, Charlotte

30046

FSGS Investigative Center, Lawrenceville

32789

FSGS Investigative Center, Winter Park

40202

FSGS Investigative Center, Louisville

43210

FSGS Investigative Center, Columbus

48201

FSGS Investigative Center, Detroit

51000

FSGS Investigative Centre, Santiago de los Caballeros

52242

FSGS Investigative Center, Iowa City

55414

FSGS Investigative Center, Minneapolis

60611

FSGS Investigative Center, Chicago

63110

FSGS Investigative Centre, St Louis

71101

FSGS Investigative Center, Shreveport

75231

FSGS Investigative Center, Dallas

75246

FSGS Investigative Center, Dallas

77030

FSGS Investigative Center, Houston

79935

FSGS Investigative Center, El Paso

80213

FSGS Investigative Center, Denver

84115

FSGS Investigative Site, Salt Lake City

07103

FSGS Investigative Center, Newark

27599-7155

FSGS Investigative Center, Chapel Hill

Unknown

FSGS Investigative Center, Santo Domingo

Sponsors
All Listed Sponsors
lead

Aurinia Pharmaceuticals Inc.

INDUSTRY